Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022604 | 0.88 | ALDH1A1 (0.34) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| SCHEMBL3019979 | 0.88 | ALDH1A1 (0.37) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| SCHEMBL3015081 | 0.87 | FKBP1A (0.33) | ALDH1A1MAPTFKBP1AGAATP53 | |
| SCHEMBL3024174 | 0.75 | GAA (0.33) | ALDH1A1MAPTFKBP1AGAATP53 | |
| SCHEMBL3023499 | 0.73 | MAPT (0.38) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| SCHEMBL3017836 | 0.72 | MAPT (0.42) | ALDH1A1MAPTFKBP1AGAA | |
| SCHEMBL3015075 | 0.72 | ALDH1A1 (0.37) | ALDH1A1KMT2ALMNAMAPTFKBP1A | |
| SCHEMBL3016583 | 0.69 | MMP2 (0.38) | ALDH1A1KMT2APOLBTP53 | |
| SCHEMBL15355170 | 0.69 | MAPT (0.40) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| SCHEMBL765596 | 0.69 | MAPT (0.40) | ALDH1A1KMT2AMEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204438-A1 | METHOD FOR PRODUCING TEDA DERIVATIVES | BASF SE (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-2197882-A2 | METHOD FOR PRODUCING TEDA DERIVATIVES | Basf Se (DE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009030649-A2 | METHOD FOR PRODUCING TEDA DERIVATIVES | BASF SE (DE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204438-A1 | METHOD FOR PRODUCING TEDA DERIVATIVES | TES, TRRAP, NAAA | ALDH1A1 720/4885KMT2A 98/4885MEN1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.